p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy.

Abstract excerpt

In this issue of Cancer Cell, Gurusamy et al. use a CRISPR-Cas9 screening approach to demonstrate that deletion of p38 increases multiple phenotypic qualities of effective anti-tumor T cells. Preconditioning T cells with a p38 inhibitor enhances anti-tumor efficacy of adoptive immunotherapy.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CRISPR-Cas Systems
• Share to Gene Editing
• Share to Immunotherapy, Adoptive